biOasis's Update on the BT2111-Herceptin(R) Program

biOasis's Update on the BT2111-Herceptin(R) Program 
VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 04/09/13 -- biOasis
Technologies Inc. (TSX VENTURE:BTI) announced today an update on the
advancement of its anti-cancer product candidate BT2111. BT2111 is a
brain-penetrating conjugate of trastuzumab (Herceptin(R)) and our
Transcend vector designed to treat brain metatastsis of HER2+ breast
cancer. Based on the exceptional data announced on February 7th of
this year, which show both a remarkable reduction on brain tumors as
well as tumor size, the company along with its expert industry
advisors has now developed the road map to take this program to the
next stage of preclinical development.  
"Through late 2011 and through 2012 the BT2111 program has delivered
tremendous results for biOasis," says Rob Hutchison, CEO. "The news
out of Texas Technical University announced on February 7th exceeded
our expectations going into the program. Based on these animal
efficacy studies we were then in a position to plan the balance of
the pre-clinical pathway. There are a number of key studies that we
will undertake as soon as possible to further evaluate and
characterize BT2111 in order to position the program for out
licensing to a pharmaceutical partner or for further internal
pre-clinical development. This work will include additional efficacy,
pharmacokinetic and safety sudies. The next efficacy study is planned
and can commence shortly and we expect to see results from this work
by mid to late summer.  
ABOUT BT2111 - BT2111 is a conjugate between biOasis' Transcend brain
delivery vector and trastuzumab (trade name of Herceptin(R)), a
humanized monoclonal antibody used clinically in the treatment of
HER2+ breast cancer. It is reported that up to 30% of HER2+ breast
cancer patients develop brain metastasis for which therapeutic
options are limited. Because of its ability to cross the blood-brain
barrier, biOasis is researching the potential of BT2111 for treatment
of HER2+ metastatic breast cancer in the brain.  
Herceptin(R) is a registered trademark of Roche/Genentech.  
ABOUT BIOASIS 
biOasis Technologies Inc. is a biopharmaceutical company
headquartered in Vancouver, Canada. Based on Transcend, biOasis
proprietary brain delivery platform, the Company is focused on
creating new drugs that can cross the blood-brain barrier to address
unmet medical needs in the treatment of brain diseases such as
neurodegeneration, metastatic cancer and metabolic diseases. biOasis
trades on the TSX Venture Exchange under the symbol "BTI". For more
information about the Company please visit www.bioasis.ca. 
Forward Looking Statements 
Certain statements in this press release contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 or forward-looking information under applicable
Canadian securities legislation that may not be based on historical
fact, including without limitation statements containing the words
"believe", "may", "plan", "will", "estimate", "continue",
"anticipate", "intend", "expect" and similar expressions. Such
forward-looking statements or information involve known and unknown
risks, uncertainties and other factors that may cause our actual
results, events or developments, or industry results, to be
materially different from any future results, events or developments
express or implied by such forward-looking statements or information.
Such factors include, among others, our stage of development, lack of
any product revenues, additional capital requirements, risk
associated with the completion of clinical trials and obtaining
regulatory approval to market our products, the ability to protect
our intellectual property, dependence on collaborative partners and
the prospects for negotiating additional corporate collaborations or
licensing arrangements and their timing. Specifically, certain risks
and uncertainties that could cause such actual events or results
expressed or implied by such forward-looking statements and
information to differ materially from any future events or results
expressed or implied by such statements and information include, but
are not limited to, the risks and uncertainties that: we may not be
able to successfully develop and obtain regulatory approval for p97
as a Physician's Aid to Diagnose Alzheimer's, or future products in
our targeted corporate objectives; our future operating results are
uncertain and likely to fluctuate; we may not be able to raise
additional capital; we may not be successful in establishing
additional corporate collaborations or licensing arrangements; we may
not be able to establish marketing and the costs of launching our
products may be greater than anticipated; we have no experience in
commercial manufacturing; we may face unknown risks related to
intellectual property matters; we face increased competition from
pharmaceutical and biotechnology companies; and other factors as
described in detail in our filings with the Canadian securities
regulatory authorities at www.sedar.com. Given these risks and
uncertainties, you are cautioned not to place undue reliance on such
forward-looking statements and information, which are qualified in
their entirety by this cautionary statement. All forward-looking
statements and information made herein are based on our current
expectations and we undertake no obligation to revise or update such
forward-looking statements and information to reflect subsequent
events or circumstances, except as required by law. 
On Behalf of the Board of Directors, 
Rob Hutchison, Chairman & CEO 
"Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of this
release" 
Contacts:
biOasis Technologies Inc.
Rob Hutchison
Chairman & CEO
(778).383.3280
rob@bioasis.ca
www.bioasis.ca
 
 
Press spacebar to pause and continue. Press esc to stop.